Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy

Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy Marshall R. Posner Oncologist 2005; 10: 11-19 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in head and neck cancers and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Explain the need for chemotherapeutic treatment for patients with squamous cell carcinoma of the head and neck. Identify the role of neoadjuvant chemotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Discuss results of randomized trials evaluating taxane-based neoadjuvant chemotherapy for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 19, 2005 Most Recent Review: Dec. 19, 2005* Most Recent Update: Dec. 19, 2005 Date Credit Expires: Dec. 19, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.